Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol
暂无分享,去创建一个
G. Karatasakis | G. Athanassopoulos | A. Anthi | E. Demerouti | A. Manginas | V. Voudris | P. Karyofyllis
[1] T. Elías-Hernández,et al. Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. , 2019, International journal of cardiology.
[2] S. Söderberg,et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.
[3] S. Rosenkranz,et al. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[4] N. Galiè,et al. Pulmonary Arterial Hypertension: Combination Therapy in Practice , 2018, American Journal of Cardiovascular Drugs.
[5] A. Torbicki,et al. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. , 2018, Journal of the American College of Cardiology.
[6] S. Rosenkranz,et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.
[7] M. Humbert,et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.
[8] K. Fukuda,et al. Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension. , 2017, The American journal of cardiology.
[9] O. Sitbon,et al. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience , 2017, European Respiratory Review.
[10] A. Ogawa,et al. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. , 2016, Journal of cardiology.
[11] J. Barberà,et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. , 2016, The Lancet. Respiratory medicine.
[12] M. Humbert,et al. Initial dual oral combination therapy in pulmonary arterial hypertension , 2016, European Respiratory Journal.
[13] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[14] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[15] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.
[16] A. Ogawa,et al. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. , 2014, Life sciences.
[17] M. Mcgoon,et al. Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry , 2014, Chest.
[18] M. Humbert,et al. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. , 2014, International journal of cardiology.
[19] Angelo Branzi,et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. , 2014, European heart journal.
[20] M. Humbert,et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.
[21] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[22] R. Benza,et al. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. , 2013, Chest.
[23] Dave P. Miller,et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[24] M. Kingman,et al. Safety recommendations for administering intravenous prostacyclins in the hospital. , 2013, Critical care nurse.
[25] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[26] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[27] R. Barst,et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. , 2013, Chest.
[28] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[29] M. Humbert,et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[30] T. Welte,et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.
[31] Sally A. Arif,et al. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. , 2011, Clinical therapeutics.
[32] A. Ogawa,et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[33] MarcHumbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010 .
[34] A. Manes,et al. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.
[35] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[36] L. Shapiro,et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[37] F. Torres,et al. Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[38] G. Simonneau,et al. The use of combination therapy in pulmonary arterial hypertension: new developments , 2009, European Respiratory Review.
[39] R. Benza,et al. Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension , 2008, International journal of clinical practice. Supplement.
[40] G. Simonneau,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.
[41] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[42] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[43] A. Negassa,et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. , 2005, European heart journal.
[44] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[45] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.
[46] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[47] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[48] R. Barst,et al. Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[49] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[50] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[51] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[52] B. Brundage,et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.
[53] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[54] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[55] J. H. Diehl,et al. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .
[56] B. Groves,et al. Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.